According to the latest quarterly report from ASGCT (American Society of Gene & Cell Therapy) , Q2 2023 proved to be a notable quarter in the field of therapy approvals, with the introduction of six new therapies that garnered regulatory clearance. Notably, both gene therapy approvals for Elevidys in Duchenne muscular dystrophy and Vyjuvek for dystrophic epidermolysis bullosa mark significant milestones as the first-ever gene therapies approved in their respective indications. The captivating advancements continued in the gene therapy realm, with an impressive increase in the number of therapies progressing to Phase II development—a growth unseen in over a year.



(Source: Biomedtracker | Citeline, July 2023)

The allure of the industry further extended to the dealmaking landscape, reaching a captivating peak in Q2 2023. Advanced molecular companies forged a total of 117 deals, showcasing a remarkable 6% increase over the aggregate of 110 deals in the preceding quarter. This surge was fueled by a reinvigorated financing scene, serving as a testament to the industry's appeal and potential. Start-up financing played a prominent role, with a remarkable $1.3 billion raised by 21 companies during the quarter—doubling the previous quarter's amount.




(Source: Biomedtracker | Citeline, July 2023)


Within this captivating period, ReNAgade Therapeutics shone bright by securing the largest Series A round of the quarter. MPM BioImpact and F2 Ventures led a mesmerizing $300 million financing for ReNAgade Therapeutics, whose RNA platform possesses the remarkable capabilities of RNA delivery, cell reprogramming, gene editing, and gene insertion.

Overall, the captivating allure of Q2 2023 showcased the industry's transformative power and attractiveness. The ground-breaking therapies, flourishing gene therapy landscape, and dynamic dealmaking environment paint a promising picture for the industry's future growth and prosperity.

One-Stop Preclinical Ophthalmology Research Solutions

As a comprehensive contract research organization (CRO) solution provider, Cyagen recognizes ophthalmic diseases as a breakthrough point for gene therapy and has established a platform to accelerate translational research of ophthalmic gene therapy. We have equipped the platform with state-of-the-art ophthalmic instruments for small animals and an experienced professional team. With 16 years of gene editing model construction experience, Cyagen can provide you with an array of standardized preclinical research solutions for ophthalmic gene therapy.

Our ophthalmic gene therapy platform is equipped with a full set of state-of-the-art ophthalmic detecting instruments which support a full range of verification services. Our ocular technologies include the Micron IV small animal retinal microscopic imaging system, full-field electroretinogram (ffERG), image-guided optical coherence tomography (OCT) system, and handheld ophthalmotonometer for mice. We can provide detection services for rodent models of eye-related diseases including diabetic retinopathy, retinoblastoma, macular degeneration, pediatric retinopathy of prematurity (ROP), choroidal neovascularization, and retinitis pigmentosa.

With 16 years of experience in the field of custom animal models, Cyagen has independently developed a series of gene editing models targeting ophthalmic diseases (e.g., retinitis pigmentosa (RP), retinal degeneration, Leber congenital amaurosis 2 (LCA2), macular degeneration, Leber congenital amaurosis 10 (LCA10), and endothelial corneal dystrophy). We can provide you with genetically engineered animal models, fully-humanized mouse models, and surgical models to accelerate your preclinical pharmacodynamics evaluations.

One-Stop Service Platform For CAR-T Therapy Research

Drawing on years of research experience in tumor immunology, Cyagen offers a full range of services to support research and development of CAR-T/-NK and other cell therapies, including antibody development, CAR molecular design, CAR lentivirus preparation, immune cell preparation and phenotype testing, cell and animal model construction, and in vitro/in vivo efficacy evaluation.

As part of our ongoing development of CRO service capabilities for CGT research, Cyagen has accumulated a wealth of CAR vector libraries and stable cell banks, and these libraries are still growing. Our goal is to provide customers with fast and convenient off-the-shelf products and accelerate research progress.

About Cyagen

Cyagen Biosciences is a 900-employee company headquartered in Santa Clara, California, with additional locations in Germany, Japan, and China. Cyagen offers a “one-stop shop” tailored to biomedical scientists’ gene research needs. Cyagen is the world's largest provider of custom-engineered mouse and rat models. Our custom murine model generation services range from DNA vector construction to embryonic stem cell manipulation, microinjection, breeding, and more. All projects are fully customizable and flexible. Cyagen provides comprehensive Contract Research Organization (CRO) services for cell and gene therapy (CGT) research, including viral vector development, CAR design and construction, disease models, phenotype analysis, and pharmacodynamic evaluations.

 

Recent Posts: